BMS Looks To Utilize Cash Reserves To Break Into Japan's Top Tier
This article was originally published in The Pink Sheet Daily
Executive Summary
Ranked 14th in pharma sales globally, the company isn't even among the top 20 pharmacos in Japan--but it plans on a change in portfolio mix and an emphasis on business development activities to change that profile.
You may also be interested in...
Don't Call It An Asset Swap: Bristol Expands Rights To Anti-PD-1 Antibody In No-Cash Transaction With Ono
In a transaction that involves no cash moving in either direction, Bristol-Myers Squibb has expanded its territorial rights to an oncology antibody acquired in its 2009 purchase of Medarex, while Ono Pharmaceutical gets co-development and co-commercialization rights to rheumatoid arthritis drug Orencia (abatacept) in Japan
Results For Bayer's Xarelto In Japanese Phase III Trial In Line With Expectations
TOKYO - Bayer AG's anticoagulant Xarelto (rivaroxaban) met its primary endpoint of clinically relevant bleeding - major and non-major bleeding - in a Japanese Phase III trial, in line with the drug's performance in a 14,000+ global Phase III study, easing the path for approval in Japan
Bristol's Focused BioPharma Strategy Starts To Pay Off
While many of the world's leading drug companies have relied on mega-mergers and diversified portfolios to drive growth over the last five years, Bristol-Myers Squibb Co. has taken a different tact, jettisoning non-core businesses, slashing overhead and jobs, and announcing a plan to focus its portfolio solely on biopharma.